| Renegociación de concesiones en Chile E Engel, R Fischer, A Galetovic, M Hermosilla Estudios Públicos 113 (113), 151-205, 2009 | 59 | 2009 |
| Pharmaceutical profits and the social value of innovation D Dranove, C Garthwaite, M Hermosilla National Bureau of Economic Research, 2014 | 57 | 2014 |
| Use of online recruitment strategies in a randomized trial of cancer survivors SP Juraschek, TB Plante, J Charleston, ER Miller, HC Yeh, LJ Appel, ... Clinical Trials 15 (2), 130-138, 2018 | 47 | 2018 |
| Market size and innovation: The intermediary role of technology licensing M Hermosilla, Y Wu Research Policy 47 (5), 980-991, 2018 | 36 | 2018 |
| Can emerging markets tilt global product design? Impacts of Chinese colorism on Hollywood castings M Hermosilla, F Gutiérrez-Navratil, J Prieto-Rodriguez Marketing Science 37 (3), 356-381, 2018 | 26 | 2018 |
| Rushed innovation: Evidence from drug licensing M Hermosilla Management Science 67 (1), 257-278, 2021 | 21 | 2021 |
| Expected profits and the scientific novelty of innovation D Dranove, C Garthwaite, MI Hermosilla National Bureau of Economic Research, 2020 | 21 | 2020 |
| Structural models of the prescription drug market AT Ching, M Hermosilla, Q Liu Foundations and Trends® in Marketing 13 (1), 1-76, 2019 | 7 | 2019 |
| Does consumer demand pull scientifically novel drug innovation? D Dranove, C Garthwaite, M Hermosilla The RAND Journal of Economics 53 (3), 590-638, 2022 | 6 | 2022 |
| Imperfect outsourcing of technological innovations M Hermosilla SSRN Scholarly Paper. Rochester, NY: Social Science Research Network, 2015 | 5 | 2015 |
| Development and commercialization strategies for new technologies: An empirical study of pre-market licensing for drug innovation M Hermosilla, Y Qian Northwestern University, 2013 | 5 | 2013 |
| Therapeutic translation of genomic science: Opportunities and limitations of gwas M Hermosilla, J Lemus Economic Dimensions of Personalized and Precision Medicine, 21-52, 2018 | 4 | 2018 |
| Does Bad Medical News Reduce Preferences for Generic Drugs? M Hermosilla, AT Ching Journal of Marketing 88 (1), 160-178, 2024 | 3 | 2024 |
| Healthcare crowd-out and resource allocation: Evidence from COVID-19 pandemic M Hermosilla, J Ni, H Wang, J Zhang Available at SSRN, 2020 | 3 | 2020 |
| Breakthrough or me-too? the impact of medicare part d on biotech innovation DS Dranove, C Garthwaite, M Hermosilla | 3 | 2014 |
| La Renegociación de Concesiones y la Nueva Ley A Galetovic, E Engel, R Fischer, M Hermosilla Puntos de Referencia 297, 2008 | 3 | 2008 |
| Ethical experimentation and regulatory flexibility in drug development M Hermosilla Available at SSRN 3731669, 2022 | 2 | 2022 |
| Search-and-Match in a Rush: Investigating Reactive Licensing in the Pharmaceutical Industry M Hermosilla Johns Hopkins Carey Business School Research Paper, 2018 | 2 | 2018 |
| Are Female-Led Trials Safer? M Hermosilla Available at SSRN 4638767, 2023 | 1 | 2023 |
| Bad Medical News and the Aversion of Generic Drugs M Hermosilla, AT Ching Available at SSRN 4026621, 2021 | 1 | 2021 |
| Leveraging the E-commerce Footprint for the Analytics of Healthcare Utilization M Hermosilla, J Ni, H Wang, J Zhang Available at SSRN 3607594, 2020 | 1 | 2020 |
| Therapeutic Translation in the Wake of the Genome M Hermosilla, JA Lemus National Bureau of Economic Research, 2017 | 1 | 2017 |
| Renegociación de Concesiones en Chile E Engel Goetz, R Fischer Barkan, A Galetovic Potsch, M Hermosilla Centro de Estudios Públicos, 2009 | 1 | 2009 |
| Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D M Hermosilla Journal of Health Economics 94, 102855, 2024 | | 2024 |
| Leveraging the E-commerce footprint for the surveillance of healthcare utilization M Hermosilla, J Ni, H Wang, J Zhang Health Care Management Science 26 (4), 604-625, 2023 | | 2023 |
| Technology Diffusion in Health Care: Understanding the Cost and Utilization of Immunotherapy in Cancer Care M Hermosilla, D Horn, M Duggan, M Jacobson, A Alpert ASHEcon 2023 Conference, 2023 | | 2023 |
| Does Bad Medical News Reduce Preferences for Generic Drugs? R Sachs, M Hermosilla, A Ching ASHEcon 2023 Conference, 2023 | | 2023 |
| Association between universal health coverage and the disease burden of acute illness and injury at the global level K Hajjar, L Lillo, DA Martinez, M Hermosilla, N Risko BMC Public Health 23 (1), 735, 2023 | | 2023 |
| COVID-19 unemployment and access to statin medications in the United States M Hermosilla, C Alexander, D Polsky Frontiers in Public Health 11, 1124151, 2023 | | 2023 |
| How does Transparency Impact Technological Novelty? Evidence from Large Pharmaceutical Firms H Tyagi, M Hermosilla, R Shah Academy of Management Proceedings 2023 (1), 13909, 2023 | | 2023 |
| Life after FDA Approval: Repurposing, Line Extensions, and Off-Label Use M Hermosilla ASHEcon 2022 Conference, 2022 | | 2022 |
| Ethical Experimentation and Regulatory Flexibility in Drug Development R McKibbin, M Hermosilla ASHEcon 2022 Conference, 2022 | | 2022 |
| Prospective adverse event risk evaluation in clinical trials A Kundu, F Feijoo, DA Martinez, M Hermosilla, T Matis Health Care Management Science, 1-11, 2022 | | 2022 |
| COVID-19 Unemployment and Access to Statin Medications in the United States (preprint) M Hermosilla, GC Alexander, D Polsky | | 2022 |
| Scientific Support for Genetically-Targeted Therapies: Investigating the Hypothesis of Technological Hype M Hermosilla, J Lemus | | 2016 |
| In this section J Lemus, M Hermosilla | | |
| Finite Sample Performance of a GMM NEIO Conductual Parameter Estimator of Market Power MI Hermosilla | | |
| CHINA INDIA INSIGHTS CONFERENCE SJ Anderson, J Cai, SJ Wei, M Hermosilla | | |
dranoveNorthwestern UniversityVerified email at kellogg.northwestern.edu
